Publications by authors named "Niveditha Popuri"
Case Rep Oncol
November 2024
Article Synopsis
- Non-small cell lung cancer (NSCLC) is the most common lung cancer type, responsible for a majority of cancer deaths globally, and advancements in treatments, especially targeted therapies like osimertinib, have improved management options.
- Osimertinib, a third-generation tyrosine kinase inhibitor, effectively targets specific mutations in the EGFR gene, including rare mutations, as exemplified by a 64-year-old woman whose unique exon 19 mutation responded well to the drug, leading to 26 months of disease control.
- The study highlights the limited research available for rare EGFR mutations and emphasizes the need for further prospective studies to better understand treatment responses and ensure safe and effective therapies for this patient group.
